- Home
- UUUU vs MLYS Comparison
UUUU vs MLYS Comparison
Compare UUUU & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUUU | MLYS |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | UUUU | MLYS |
|---|---|---|
| Price | $23.01 | $31.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $17.00 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 13.2M | 1.2M |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 103.69 | N/A |
| 52 Week Low | $3.20 | $8.24 |
| 52 Week High | $27.33 | $47.65 |
Technical Indicators
Market Signals| Indicator | UUUU | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 30.45 |
| Support Level | $20.88 | $30.96 |
| Resistance Level | $24.35 | $33.64 |
| Average True Range (ATR) | 1.80 | 1.55 |
| MACD | 0.54 | -0.18 |
| Stochastic Oscillator | 86.17 | 4.53 |
Price Performance
Historical ComparisonAbout UUUU Energy Fuels Inc (Canada)
Energy Fuels Inc is a United States-based critical minerals company. The Company mines uranium and produces natural uranium concentrates that are sold to nuclear utilities for the production of carbon-free nuclear energy. It holds two of America's key uranium production centers: The White Mesa Mill in Utah, and the Nichols Ranch ISR Facility in Wyoming. It has three reportable segments based on its operations and financial information; Uranium, HMS, and REE.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.